Age-related changes in nitric oxide activity, cyclic GMP, and TBARS levels in platelets and erythrocytes reflect the oxidative status in central nervous system

Kawamoto, Elisa Mitiko; Vasconcelos, Andréa Rodrigues; Degaspari, Sabrina; Böhmer, Ana Elisa; Scavone, Cristóforo; Marcourakis, Tânia

doi:10.1007/s11357-011-9365-7

Cited by 27 publications

(21 citation statements)

References 49 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TBARS increased with age in erythrocytes [43] and were reported to be lower in females compared to males [44]. TBARS increased with increasing physical fitness [10].…”

Section: Reviewmentioning

confidence: 99%

Biomarkers of peripheral muscle fatigue during exercise

Finsterer

2012

BMC Musculoskelet Disord

235

216

View full text Add to dashboard Cite

BackgroundBiomarkers of peripheral muscle fatigue (BPMFs) are used to offer insights into mechanisms of exhaustion during exercise in order to detect abnormal fatigue or to detect defective metabolic pathways. This review aims at describing recent advances and future perspectives concerning the most important biomarkers of muscle fatigue during exercise.ResultsBPMFs are classified according to the mechanism of fatigue related to adenosine-triphosphate-metabolism, acidosis, or oxidative-metabolism. Muscle fatigue is also related to an immunological response. impaired calcium handling, disturbances in bioenergetic pathways, and genetic responses. The immunological and genetic response may make the muscle susceptible to fatigue but may not directly cause muscle fatigue. Production of BPMFs is predominantly dependent on the type of exercise. BPMFs need to change as a function of the process being monitored, be stable without appreciable diurnal variations, correlate well with exercise intensity, and be present in detectable amounts in easily accessible biological fluids. The most well-known BPMFs are serum lactate and interleukin-6. The most widely applied clinical application is screening for defective oxidative metabolism in mitochondrial disorders by means of the lactate stress test. The clinical relevance of most other BPMFs, however, is under debate, since they often depend on age, gender, physical fitness, the energy supply during exercise, the type of exercise needed to produce the BPMF, and whether healthy or diseased subjects are investigated.ConclusionsThough the role of BPMFs during fatigue is poorly understood, measuring BPMFs under specific, standardised conditions appears to be helpful for assessing biological states or processes during exercise and fatigue.

show abstract

“…TBARS increased with age in erythrocytes [43] and were reported to be lower in females compared to males [44]. TBARS increased with increasing physical fitness [10].…”

Section: Reviewmentioning

confidence: 99%

Biomarkers of peripheral muscle fatigue during exercise

Finsterer

2012

BMC Musculoskelet Disord

235

216

View full text Add to dashboard Cite

show abstract

“…Phosphodiesterase 9A inhibition by 69 demonstrated an increase in basal synaptic transmission and enhanced LTP better in older rats compared to younger rats [197]. This is likely due to age-related decreases in cGMP levels [159,236] rather than changes in PDE9A expression levels, which have been shown to change during developmental stages [154], but do not significantly differ between young and old rats [237]. Additionally, expression of PDE9A in post-mortem brain tissue of patients with Alzheimer's disease shows the same distribution as in healthy brain tissues of comparable age [156].…”

Section: Clinical Trialsmentioning

confidence: 96%

The Use of PDE10A and PDE9 Inhibitors for Treating Schizophrenia

Tuttle

Kormos

2014

Small Molecule Therapeutics for Schizophrenia

View full text Add to dashboard Cite

Schizophrenia (Scz) is a chronic and debilitating neurological disorder that afflicts approximately 1% of the general population with an increased incidence within families. Signs of this disorder typically appear between the ages of 16-30 although rare cases of childhood (<13) onset exist. Diagnosis of scz requires symptoms that persist for a duration of 1 month over a 6-month time period. The broad spectrum of symptoms are typically split into three categories: positive, negative, and cognitive. Implicit within these categories is the difficulty for stand-alone treatment methods, suggesting a combination of pharmacological and psychological treatment strategies is needed to manage this disease. Furthermore, while current pharmaceuticals are moderately effective at managing positive symptoms, the severe side effects lower patient compliance. Additionally, drugs used to treat negative and cognitive symptoms only have modest benefits, at best. Due to these limitations, there is a clear need for novel pharmaceuticals that modulate dysfunctional neurological pathways in scz patients. As such, both academic and pharmaceutical researchers are focused on identifying enzymes that can attenuate neurological signaling in disease-relevant brain regions. Specifically, this chapter will provide an in-depth review of current drug discovery efforts focused on inhibiting phosphodiesterase 10 and 9 (PDE10A, PDE9A, respectively).

show abstract

“…Its unremarkable safety profile can be interpreted as demonstrating the safety of both 5HT 3 R antagonist and α7 nAChR partial agonist mechanistic approaches. The 236 A. Mazurov and D. Yohannes discovery that tropisetron is also a potent partial agonist for α7 nAChRs gives cause for the reexamination of both clinical and preclinical findings with this compound, particularly when it displayed pharmacological effects different from other 5HT 3 R antagonists. It was reported that the 5HT 3 R antagonists tropisetron and ondansetron had qualitatively different results in learning and memory paradigms in rats [172]; tropisetron, but not the selective 5-HT 3 R antagonist ondansetron, attenuated PCPinduced cognitive deficits in mice, and this effect of tropisetron was blocked by coadministration of the selective α7 nAChR antagonist MLA [173].…”

Section: α7 Nachr Agonists For Schizophreniamentioning

confidence: 99%

Section: Summary Outlook Conclusionmentioning

confidence: 99%

Small Molecule Therapeutics for Schizophrenia

Célanire¹,

Poli²

2015

Topics in Medicinal Chemistry

View full text Add to dashboard Cite

Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the new topic-related series Topics in Medicinal Chemistry will cover all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics.In general, special volumes are edited by well known guest editors.In references Topics in Medicinal Chemistry is abbreviated Top Med Chem and is cited as a journal.More information about this series at

show abstract

Age-related changes in nitric oxide activity, cyclic GMP, and TBARS levels in platelets and erythrocytes reflect the oxidative status in central nervous system

Cited by 27 publications

References 49 publications

Biomarkers of peripheral muscle fatigue during exercise

Biomarkers of peripheral muscle fatigue during exercise

The Use of PDE10A and PDE9 Inhibitors for Treating Schizophrenia

Small Molecule Therapeutics for Schizophrenia

Contact Info

Product

Resources

About